Clinical Trial to Evaluate the Efficacy and Safety of YHP2401 Compared to YHR2402 and YHR2403 for Acute Bronchitis

Launched by YUHAN CORPORATION · Aug 1, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new medicine called YHP2401 to see if it works better and is as safe as two other treatments, YHR2402 and YHR2403, for people with acute bronchitis. Acute bronchitis is a condition where the airways in the lungs become inflamed, causing a cough that produces mucus. The study is currently looking for participants and is being done at multiple locations.

Adults between the ages of 19 and 80 who have had a productive cough (meaning coughing up mucus) for less than two days and have certain symptoms like a noticeable cough and mucus production may be eligible to join. Participants will need to agree to take part and meet some health criteria, such as not having severe lung disease or other serious lung infections. If you join, you will be randomly assigned to receive one of the three treatments without knowing which one, and doctors will monitor your symptoms and safety throughout the study. This trial aims to find out if YHP2401 can help people get better faster and with fewer side effects than the other options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male and female participants 19 years ≤ age ≤ 80 years
• • Patients with acute bronchitis presenting with productive cough symptoms within 48 hours prior to Visit 2 (Baseline)
• • BSS total score ≥ 5 at Visit 2, including Cough score ≥ 2, Sputum score ≥ 1
• • Patients who voluntarily signed the consent form
• Exclusion Criteria:
• • Severe lung disease as determined by the investigator
• • Clinically significant abnormal findings or signs on chest X-ray suggesting diagnoses other than acute bronchitis
• • Active infection requiring systemic antibiotic treatment
• • Patients who need to take contraindicated concomitant medications